News — Chugai Venture Fund

NEWS

What’s New in the CVF Portfolio?

Sept 30, 2026

Forbes: Built To Connect: How Chugai Turns Scientific Quality Into Global Partnership

Sept 17, 2026

Dualitas Therapeutics Announces Proximity Biology Research Collaboration with Roche to Discover and Develop Novel Bispecific Antibodies for I&I Diseases

Aug 17, 2026

Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia

Feb 19, 2026

Ten63 Therapeutics Closes Strategic Financing, Bringing Total Funding to More Than $45M to Scale the Next-Generation of Artificial Intelligent Drug Discovery

Jan 29, 2026

Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases

Jan 16, 2026 ‍

Fierce Biotech: JPM26: Chugai chases new science and name recognition from US biopharma industry

2026

Sep 16, 2025
Dualitas Launches With $65 Million Series A to Advance Novel Bispecific Antibody Pipeline in Immune and Inflammatory Disease

May 13, 2025
Stylus Medicine Launches to Develop Precision, In Vivo Genetic Medicines and Unlock the Full Potential of CAR-T Therapy

2025

Nov 12, 2024
Hyku Biosciences Appoints John Gustofson to its Board of Directors

2024

Jun 27, 2023
Chugai Establishes Corporate Venture Capital to Accelerate Innovation Opportunities with Drug Discovery Start-ups